Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma

Переверзева, Э. Р.; Treschalin, I. D.; Treschalin, M. I.; Arantseva, Diana; Ermolenko, Yulia; Kumskova, Natalya; Maksimenko, Olga; Balabanyan, Vadim; Kreuter, Jörg; Gelperina, Svetlana

doi:10.1016/j.ijpharm.2018.11.014

Cited by 64 publications

(32 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 33.65 ± 3.93 µg/mg of the stabilizer was adsorbed. This was in line with previous findings and corresponded to an amount of 0.90 ± 0.08 µg/m 2 (µg per nanoparticle surface area) [30]. Additionally, this adsorption increased the particle diameter by 11 nm as compared to the particles without surfactant.…”

Section: Physicochemical Characterization Of Nanoparticlessupporting

confidence: 92%

“…Consequently, the amount of poloxamer adsorbed to the nanoparticle surface was quantified. Each formulation was analyzed using a modified iodometric method as described previously [30]. It is based on the interaction of poloxamer 188 with iodine leading to the formation of colored compounds with a characteristic absorption maximum (λ ex 501 nm) [52].…”

Section: Evaluation Of Poloxamer 188 Contentmentioning

confidence: 99%

See 1 more Smart Citation

Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin

et al. 2021

Self Cite

View full text Add to dashboard Cite

Targeted delivery of doxorubicin still poses a challenge with regards to the quantities reaching the target site as well as the specificity of the uptake. In the present approach, two colloidal nanocarrier systems, NanoCore-6.4 and NanoCore-7.4, loaded with doxorubicin and characterized by different drug release behaviors were evaluated in vitro and in vivo. The nanoparticles utilize a specific surface design to modulate the lipid corona by attracting blood-borne apolipoproteins involved in the endogenous transport of chylomicrons across the blood–brain barrier. When applying this strategy, the fine balance between drug release and carrier accumulation is responsible for targeted delivery. Drug release experiments in an aqueous medium resulted in a difference in drug release of approximately 20%, while a 10% difference was found in human serum. This difference affected the partitioning of doxorubicin in human blood and was reflected by the outcome of the pharmacokinetic study in rats. For the fast-releasing formulation NanoCore-6.4, the AUC0→1h was significantly lower (2999.1 ng × h/mL) than the one of NanoCore-7.4 (3589.5 ng × h/mL). A compartmental analysis using the physiologically-based nanocarrier biopharmaceutics model indicated a significant difference in the release behavior and targeting capability. A fraction of approximately 7.310–7.615% of NanoCore-7.4 was available for drug targeting, while for NanoCore-6.4 only 5.740–6.057% of the injected doxorubicin was accumulated. Although the targeting capabilities indicate bioequivalent behavior, they provide evidence for the quality-by-design approach followed in formulation development.

show abstract

Section: Physicochemical Characterization Of Nanoparticlessupporting

confidence: 92%

Section: Evaluation Of Poloxamer 188 Contentmentioning

confidence: 99%

Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Primary emulsion (dox in 0.001n HCl and PLGA in DCM) was processed through ultra turrax (23,000-24,000 rpm, 5 min) and double emulsion obtained after addition PVA in PBS solution was again homogenized in Ultra Turrax T-25 (23,000-24,000 rpm, 20 min) then passed through HPH 10000 psi and 3 cycles. They were able to achieve particles with mean hydrodynamic diameter of approximately 94 nm [71].…”

Section: Doxorubicinmentioning

confidence: 99%

Quality by design (QbD) approach in processing polymeric nanoparticles loading anticancer drugs by high pressure homogenizer

Soni

Kale

Shetty

et al. 2020

Heliyon

View full text Add to dashboard Cite

Polymeric nanoparticles prepared using high pressure homogenizer (HPH) present some unique challenges during manufacturing which can be better understood by application of quality by design (QbD) approaches. The present review highlights the ways to identify the critical material attributes which includes the anticancer drugs, polymers, surfactants, solvent system and dispersion system. A comprehensive understanding of the critical processing parameters like pressure and number of cycles during the working of HPH used in putting forward the critical quality attributes such as size, shape, surface charge or droplet stabilization. Such QbD approach will involve development of an effective control strategy for would ensure safe encapsulation of anticancer drugs for successful product development. Proper addressing of the issues related to scaling-up would lead to successful commercialization of the nano-sized formulations loaded with anticancer drugs.

show abstract

“…Another study indicated that the docetaxel-loaded poly (ε-caprolactone)/Pluronics F68 achieved significant cytotoxicity in the docetaxel-resistance human breast cancer cell line [16]. Additionally, doxorubicin-loaded Pluronics F68-coated PLGA nanoparticles exhibited an antitumor effect against the experimental orthotopic 101.8 glioblastomas in rats upon intravenous administration [17]. Previous studies have evaluated the synthesis of PLGA with many different poloxamers, including Pluronics F68 [18,19].…”

Section: Introductionmentioning

confidence: 99%

Formulation, Characterization and Cytotoxicity Effects of Novel Thymoquinone-PLGA-PF68 Nanoparticles

Noor

Kaus

Szewczuk

et al. 2021

IJMS

View full text Add to dashboard Cite

Thymoquinone has anti-cancer properties. However, its application for clinical use is limited due to its volatile characteristics. The current study aims to develop a polymeric nanoformulation with PLGA-PEG and Pluronics F68 as encapsulants to conserve thymoquinone’s (TQ) biological activity before reaching the target sites. Synthesis of nanoparticles was successfully completed by encapsulating TQ with polymeric poly (D, L-lactide-co-glycolide)-block-poly (ethylene glycol) and Pluronics F68 (TQ-PLGA-PF68) using an emulsion–solvent evaporation technique. The size and encapsulation efficiency of TQ-PLGA-PF68 nanoparticles were 76.92 ± 27.38 nm and 94%, respectively. TQ released from these encapsulants showed a biphasic released pattern. Cytotoxicity activity showed that tamoxifen-resistant (TamR) MCF-7 breast cancer cells required a higher concentration of TQ-PLGA-PF68 nanoparticles than the parental MCF-7 cells to achieve IC50 (p < 0.05). The other two resistant subtypes (TamR UACC732 inflammatory breast carcinoma and paclitaxel-resistant (PacR) MDA-MB 231 triple-negative breast cell line) required a lower concentration of TQ-PLGA-PF68 nanoparticles compared to their respective parental cell lines (p < 0.05). These findings suggest that TQ encapsulation with PLGA-PEG and Pluronics F68 is a promising anti-cancer agent in mitigating breast cancer resistance to chemotherapeutics. In future studies, the anti-cancer activity of TQ-PLGA-PF68 with the standard chemotherapeutic drugs used for breast cancer treatment is recommended.

show abstract

Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma

Cited by 64 publications

References 56 publications

Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin

Exploring the Interplay between Drug Release and Targeting of Lipid-Like Polymer Nanoparticles Loaded with Doxorubicin

Quality by design (QbD) approach in processing polymeric nanoparticles loading anticancer drugs by high pressure homogenizer

Formulation, Characterization and Cytotoxicity Effects of Novel Thymoquinone-PLGA-PF68 Nanoparticles

Contact Info

Product

Resources

About